SCHEMBL26962286

SCHEMBL26962286

CC(C)(C)OC(=O)N[C@H]1CS(=O)(=O)c2ccc(-c3nnc(C4(C)CCN(C(=O)OCc5ccccc5)CC4)o3)cc2N(Cc2ccc(Cl)cc2)C1=O

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TRPC3 Q13507 1/20 0.36
▸ TRPC7 Q9HCX4 1/20 0.36
▸ THRB P10828 2/20 0.35
▸ NPY1R P25929 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ OPRD1 P41143 2/20 0.32
▸ OPRK1 P41145 2/20 0.32
▸ GPR119 Q8TDV5 2/20 0.32
▸ UTS2R Q9UKP6 1/20 0.32
▸ CNR1 P21554 1/20 0.32
▸ CNR2 P34972 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ PDE4B Q07343 1/20 0.31
▸ MAPK8 P45983 1/20 0.31
▸ CCR1 P32246 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26961929 0.91 PDK2 (0.34) THRBSMN1; SMN2GPR119CCR1
SCHEMBL26962039 0.88 XIAP (0.36) TRPC3TRPC7NPY1RALDH1A1GPR119
SCHEMBL26961932 0.87 NPY1R (0.32) NPY1RCNR2CCR1
SCHEMBL26961807 0.85 SMN1; SMN2 (0.34) THRBSMN1; SMN2GPR119CNR1CNR2
SCHEMBL26962322 0.85 PDE4B (0.33) TRPC3TRPC7THRBNPY1RALDH1A1
SCHEMBL26961895 0.82 THRB (0.35) TRPC3TRPC7THRBNPY1RALDH1A1
SCHEMBL26962164 0.81 PDK2 (0.33) NPY1RSMN1; SMN2CCR1
SCHEMBL26961707 0.81 CCR1 (0.33) NPY1RCCR1
SCHEMBL26961147 0.79 PDK2 (0.34) THRBALDH1A1MAPTGPR119GAA
SCHEMBL26961749 0.78 AKT1 (0.33) THRBNPY1RMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4291558-A1 BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2023-12-20 — — EP disclosed
Send feedback